Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Patricia Fonseca , Raphael Rosenhek , Vinayak Bapat , et al Added: 3 years ago
Degenerative aortic stenosis (AS) is a chronic progressive valvular disease that affects approximately 1.4 % of individuals over 65 years and 4.6 % of patients older than 75 years in the US.1 While the prognosis of asymptomatic patients with severe AS is generally good, that of symptomatic patients is very poor, with an overall mortality of approximately 80 % at three years once the disease… View more

Vascular Disease and Surgery

Intervention
Antithrombotic Therapy After Transcatheter Aortic Valve Implantation
Author(s): Leslie Marisol Lugo , Rafael Romaguera , Joan Antoni Gómez-Hospital , et al Added: 3 years ago
Transcatheter aortic valve implantation (TAVI) is the therapy of choice for patients with symptomatic severe aortic stenosis who are unsuitable for surgical aortic valve replacement and for elderly patients with high operative risk.1,2 It is also considered to be a more than valid and reasonable alternative to surgical aortic valve replacement for patients with moderate to high surgical risk.3,4… View more

Anticoagulation
Age and Sex Impact on Intervention For Aortic Stenosis
Author(s): Nina Rashedi , Catherine M Otto Added: 1 year ago

Imaging & Diagnostics
Under-representation of Women in Structural Interventional Cardiology
Author(s): Sonya Burgess , F Aaysha Cader , Elizabeth Shaw , et al Added: 1 year ago

Demographic

Intervention
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Author(s): Martin B Leon Added: 4 months ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic… View more

Intervention
TAVI in Challenging Scenarios
Author(s): Sandra Santos-Martínez , Ignacio J Amat-Santos Added: 2 years ago

Vascular Disease and Surgery
USC Discussion 2022: Transcatheter Aortic Valve Replacement Optimization Strategies
Author(s): Hemal Gada , Kendra J Grubb Added: 1 year ago
Dr Hemal Gada (UPMC Heart and Vascular Institute, US) and his team published an informative review article on “Transcatheter Aortic Valve Replacement Optimization Strategies: Cusp Overlap, Commissural Alignment, Sizing, and Positioning”, in a comprehensive special focus issue on the “Lifetime Management of Patients With Aortic Stenosis” edited byDr Kendra Grubb(Emory Structural Heart and Valve… View more

Vascular Disease and Surgery

Intervention
Management of Coronary Disease in TAVI Patients
Author(s): Antonio FB de Azevedo Filho , Tarso AD Accorsi , Henrique B Ribeiro Added: 2 years ago

Vascular Disease and Surgery
CRT 2019: Portico Self-Expanding Aortic Valve
Author(s): Augusto D Pichard Added: 5 years ago
Prof Augusto Pichard (MedStar Washington Hospital Center, Washington DC, US) discusses the Portico self-expanding aortic valve - latest iterations and status of trial. Filmed on site at CRT 2019 by Radcliffe Cardiology. Questions: 1. Could you give us a brief narrative of data published on the Portico valve to date? 2. Which patients do you use the Portico Valve in? 3. For implantors, not… View more

Intervention
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Author(s): Michael J Reardon Added: 5 months ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more

Intervention